早些时候报道，Innoviva Specialty Thereutics报告了III期Zoliflodacin结果发表在《柳叶刀》上，FDA NDA于2025年6月和12月接受PDUFA目标

2025-12-12 16:25

Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea.
Positive study results are a significant milestone in the development of a first-in-class single-dose, oral antibiotic against gonorrhea, including infections caused by drug-resistant Neisseria gonorrhoeae, an urgent public health threat and high-priority pathogen.
Gonorrhea is the second most reported bacterial STI in the United States, with resistance to first-line treatment emerging.